ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 692

Association Between Improvement in Enthesopathy and Quality of Life: Results from a Phase 3 T in Psoriatic Arthritis Patients

Arthur Kavanaugh1, Luis Puig2, Alice B. Gottlieb3, Christopher T. Ritchlin4, Yin You5, Shu Li5, Michael Song5, Proton Rahman6 and Iain. B. McInnes7,8, 1University of California San Diego, La Jolla, CA, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Tufts Medical Center, Boston, MA, 4Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 5Janssen Research & Development, LLC, Spring House, PA, 6Rheumatology, Memorial University of Newfoundland, St Johns, NF, Canada, 7Institute of Biomedical and Environmental Health Research, University of the West of Scotland, Glasgow, United Kingdom, 8Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: enthesopathy and quality of life, Health Assessment Questionnaire

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the relationship between improvement or worsening in
enthesopathy and changes in functioning and quality of life (QOL) in patients
with psoriatic arthritis (PsA).

Methods:
Adult PsA patients (n=615) with active disease (≥5 SJC and ≥5
TJC;CRP≥0.3mg/dL) despite DMARD and/or NSAIDs were randomized to UST45mg,
90mg, or PBO at weeks 0, 4, and q12weeks. Patients treated with prior anti-TNF
agents were excluded. Stable concomitant MTX was permitted but not mandated. At
week16, pts with <5% improvement in TJC & SJC entered blinded early
escape (PBO→UST45mg; UST45mg→90mg; 90mg→90mg). Presence or absence of enthesopathy, HAQ and SF-36 were
assessed at baseline and week 24.  In this post-hoc analysis, the enthesopathy was
focused on the Achilles tendon and plantar fascia and was assessed as present
or absent. Patients were categorized for enthesopathy into three categories:
improved (enthesopathy present at baseline, but not at week 24), worsened
(enthesopathy present at week 24, but not at baseline), and unchanged. 
Patients with an enthesopathy assessment missing at either time point were
included in the unchanged category.  Improvements in quality of life (assessed
by the Short Form-36 mental and physical component scores [SF-36 PCS and SF-36
MCS] and physical function (assessed by the Health Assessment
Questionnaire-Disability Index [HAQ-DI]) were assessed by enthesopathy status.

 

Results:  80% of patients (n=491) reported enthesitis at baseline, and the
proportion of patients with enthesopathy was similar in the combined ustekinumab
(47.2%) and placebo (52.1%) groups.  At week 24, the proportions of patients
with enthesopathy were 23.2% and 38.2% for the combined ustekinumab and placebo
groups, respectively.  Across all
patients, those who had an improvement in enthesopathy had a greater
improvement in functioning and QOL, compared with those who did not (Table).  The
results were consistent when the analysis was done separately for each
treatment group.  Even when the analysis was restricted to those who achieved
an ACR 20 response, patients with an improvement in enthesopathy still showed a
greater improvement in functioning and QOL compared to those who did not
(Table).

 

Table  Enthesopathy
status and mean (SD) changes from baseline at week 24

 

Enthesopathy Status

 

Worsened

Unchanged

Improved

Overall

% improvement in HAQ-DI

n=21

17.7(35.9)

n=339

22.6(66.0)

n=113

37.5(47.0)

Change in SF-36 PCS

n=22

4.1(7.1)

n=333

4.9(8.7)

n=116

6.7(9.1)

Change in SF-36 MCS

n=22

-1.5(8.8)

n=333

3.5(10.1)

n=116

6.7(9.6)

ACR 20 responders

% improvement in HAQ-DI

 

n=8

33.7(32.8)

n=145

52.8(37.0)

n=72

53.4(39.1)

Change in SF-36 PCS

n=8

8.7(7.4)

n=150

8.7 (8.8)

n=72

9.5(8.8)

Change in SF-36 MCS

n=8

3.5(8.0)

n=150

5.2(10.2)

n=72

7.7(9.4)

Conclusion:   Ustekinumab treatment can significantly
improve enthesopathy associated with psoriatic arthritis.There is an
association between improvement in enthesopathy of the Achilles tendon and
plantar fascia and improvement in physical function and quality of life in
patients with PsA. 

 


Disclosure: A. Kavanaugh, Janssen R & D, LLC, 2; L. Puig, Janssen R & D, LLC, 2; A. B. Gottlieb, Janssen R & D, LLC, 2; C. T. Ritchlin, Janssen Scientific Affairs, LLC, 2; Y. You, Janssen R & D, LLC, 3; S. Li, Janssen R & D, LLC, 3; M. Song, Janssen R & D, LLC, 3; P. Rahman, Janssen R & D, LLC, 2; I. B. McInnes, Janssen R & D, LLC, 2.

To cite this abstract in AMA style:

Kavanaugh A, Puig L, Gottlieb AB, Ritchlin CT, You Y, Li S, Song M, Rahman P, McInnes IB. Association Between Improvement in Enthesopathy and Quality of Life: Results from a Phase 3 T in Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/association-between-improvement-in-enthesopathy-and-quality-of-life-results-from-a-phase-3-t-in-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-improvement-in-enthesopathy-and-quality-of-life-results-from-a-phase-3-t-in-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology